Apr 6, 2021

NSG and Acclivis sign deal to develop AI genomics workflow

AI
Genomics
cloudtechnology
Cancer
Leila Hawkins
2 min
NSG and Acclivis sign deal to develop AI genomics workflow
Singapore company NSG signs an MOU with Acclivis to create a new cloud-based workflow for its AI genomics platform...

New Silkroutes Group Limited (NSG), a Singaporean investment holding company, has signed a Memorandum of Understanding (MOU) with cloud provider Acclivis Technologies and Solutions to develop a new solution for an artificial intelligence (AI) platform that provides genomic-driven healthcare. 

The non-binding MOU covers the development of a private AI cloud facility and secure network connection that will pull genomics data from cloud data storage to produce clinical reports for medical practitioners and clinicians. The system will have machine learning capability, so that the clinical reports it produces will become more intelligent over time, increasing usage. 

Through its subsidiary Healthsciences International Pte Ltd, NSG owns a number of primary care and dental facilities in Singapore and Vietnam, as well as pharmacy management systems in Singapore and China. The company will own the intellectual property rights for the new workflow and the user interface of the platform. 

Dr VicPearly Wong, NSG’s Chief Executive Officer said that the solution - called GEIATM - is a complete, seamless, hybrid cloud-based solution. “We have been working hard to enhance our AI capabilities to transform ourselves into a tech-enabled healthcare group that will provide patients with the best diagnosis and treatment. We look forward to launching GEIATM , our very own AI solution soon" he said. 

Mr Marcus Cheng, Chief Executive Officer of Acclivis, added: “Acclivis has a track record of building and managing private cloud facilities and developing AI technology platforms that define, structure and automate workflows for the public, commercial and healthcare sectors. We are delighted to partner with NSG to positively shape the future of genomics healthcare.”

NSG is currently focused on becoming a leading health tech player in the Asia Pacific region. Earlier this year the firm entered into a collaboration with Huawei to develop its AI-driven platform, to build predictive models for cancer along with other conditions. 

“NSG will continue to build relationships with leading tech players who can provide us with a full range of capabilities in data-driven diagnostics” Dr Wong added. 

Share article

Jun 16, 2021

NHS opens 8 clinical trial sites to assess cancer treatment

NHS
Cancer
immunotherapy
MachineLearning
2 min
NHS and OncoHost to launch clinical trials analysing cancer patients response to immunotherapy

The UK's National Health Service (NHS) is opening eight clinical trial sites to assess patients' responses to personalised cancer therapy. 

The trials will analyse how patients diagnosed with advanced melanoma or non-small cell lung cancer respond to immunotherapy, to help predict their response to treatment.  They will be hosted at Gloucestershire Hospitals NHS Foundation Trust facilities. 

Immunotherapy helps the body's own immune system fight cancer, but while it has achieved good results for some cancer patients, it is not successful for everyone. Finding ways to predict which people will respond to the treatment is a major area of research.

OncoHost, an oncology startup,  will provide advanced machine learning technology to develop personalised strategies aiming to improve the success rate of the cancer therapy. The trials will contribute to OncoHost’s ongoing PROPHETIC study, which uses the company’s host response profiling platform, PROphet®

“Immunotherapy has achieved excellent results in certain situations for several cancers, allowing patients to achieve longer control of their cancer with maintained quality of life and longer survival,” said Dr David Farrugia, Consultant Medical Oncologist at NHS, and chief investigator of all eight NHS clinical trial sites.

“However, success with immunotherapy is not guaranteed in every patient, so this PROPHETIC study is seeking to identify changes in proteins circulating in the blood which may help doctors to choose the best treatment for each patient." 

"I am excited that Gloucestershire Oncology Centre and its research department have this opportunity to contribute to this growing field of research and I am determined that our centre will make a leading national contribution in patient recruitment.”

Previous studies in the US and Israel have shown that PROphet® has high accuracy in predicting how patients with cancer will respond to various therapies.

Share article